NovaBridge Biosciences Income (Loss) from Equity Method Investments
NovaBridge Biosciences (NBP) reported Income (Loss) from Equity Method Investments of -$1.04 million for the 12-month period ending 2024-12-31, per its 20-F filed 2026-04-07.
Financial Statements › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2026-04-07
CNY
| Period end | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|
| 2023-12-31 | -80.02M CNY 20-F · filed 2024-04-30 | |
| 2022-12-31 | -437.46M CNY 20-F · filed 2024-04-30 | |
| 2022-06-30 | -181.02M CNY 6-K · filed 2022-11-10 | |
| 2021-12-31 | -367.88M CNY 20-F · filed 2024-04-30 | |
| 2021-06-30 | -114.20M CNY 6-K · filed 2022-11-10 | |
| 2020-12-31 | -108.59M CNY 20-F · filed 2023-05-01 | |
| 2019-12-31 | 0.00 CNY 20-F · filed 2022-04-29 |
USD
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month | Income (Loss) from Equity Method Investments 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 20-F 12 month − 6-K 9 month · filed 2026-04-07 | $0.00 derived: sum of 2 quarters · filed 2026-04-07 | -$1.04M 20-F · filed 2026-04-07 | ||
| 2024-09-30 | $0.00 derived: 6-K 9 month − 6-K 6 month · filed 2025-12-18 | -$1.04M 6-K · filed 2025-12-18 | |||
| 2024-06-30 | -$1.04M 6-K · filed 2025-10-06 | ||||
| 2023-12-31 | -$11.40M 20-F · filed 2026-04-07 | -$11.27M 20-F · filed 2024-04-30 | |||
| 2022-12-31 | -$64.71M 20-F · filed 2025-04-03 | -$63.43M 20-F · filed 2023-05-01 | |||
| 2022-06-30 | -$27.03M 6-K · filed 2022-11-10 | ||||
| 2021-12-31 | -$57.73M 20-F · filed 2022-04-29 | ||||
| 2020-12-31 | -$16.64M 20-F · filed 2021-04-28 |